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Abstract
Background: Patients with Pulmonary tuberculosis (PTB) and hypocholesterolemia have an altered immune function, delayed 
sputum conversion at two months and increased mortality.  However, the assessment for dyslipidemias is not often done in our 
setting.
Methods: A cross-sectional study was conducted among adults at an urban TB clinic in Kampala, Uganda. We included different 
participants at diagnosis (0), 2, 5, 6 and 8 months of  anti-TB treatment. Data was collected from a complete physical examina-
tion, a pre-tested structured questionnaire, six-hour fasting lipid profiles and random blood glucose levels.
Results: Of  the 323 included participants, 63.5% (205/323) were males and the median age was 30 years, IQR (23-39). The 
prevalence of  hypocholesterolemia was 43.65% (95% CI 38.3-49.2). The participants at diagnosis had the highest hypocholes-
terolemia prevalence, 57.3%, 95% CI (46.7-67.2); and lowest amongst those completing treatment at 6/8 months, 32.2%, 95% 
CI (21.6-45.2). Significant factors associated with hypocholesterolemia were: male gender (PR 1.52, 95% CI: 1.13-2.03), and 
duration of  anti-TB treatment (0.88, 95% CI: 0.80-0.98).
Conclusion: Hypocholesterolemia is common among patients with PTB. The risk of  hypocholesterolemia increases with being 
male and reduces with increased duration of  treatment. There is a need for further research in lipid abnormalities in TB patients.
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Introduction                                               
Pulmonary Tuberculosis (PTB) is still a major global 
health problem estimated to cause 10.4 million new cases 
and 1.8 million related deaths annually1,2.  Africa bears 
about 25% of  the world's PTB cases and yet it has the 
lowest number of  health professionals, with the major-
ity of  sub-Saharan Africa countries like Uganda having 
less than 5 physicians per 1000 population3.  The inci-
dence of  PTB in Africa is estimated at 280 per 100,000 
compared to the global incidence of  126 per 100000. In 
comparison, Uganda has an estimated incidence of   TB 
at 202/100000 population2.
PTB patients often have deranged serum lipid levels, 
especially low cholesterol levels (hypocholesterolemia) 
which are an important cause of  morbidity4. The hypo-
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cholesterolemia in PTB patients has been shown to al-
ter the body immunity,  and could possibly be associated 
with delayed sputum conversion and increased mortality 
especially in circumstances of  drug resistance5.
Lipid abnormalities in PTB patients are associated with 
Anti-retroviral therapy (ART) especially Non-Nucleoside 
Reverse Transcriptase Inhibitors (NNRTIs) and Protease 
Inhibitors (PIs), HIV, malnutrition, cavitary disease on 
the X-ray and older age6-9. However, the characterization 
of  lipid abnormalities in sub-Saharan Africa which has a 
high prevalence of  HIV and malnutrition is not well doc-
umented10,11. In Uganda, the WHO and National TB and 
Leprosy Programme (NTLP) recommend clinical, bacte-
riological, nutritional assessment and monitoring of  TB 
patients at diagnosis and throughout the course of  treat-
ment but this is rarely done and if  performed only stops 
at anthropometric measurements12,13.  This paper, there-
fore, presents the prevalence and factors associated with 
hypocholesterolemia among adult PTB patients either at 
diagnosis, 2, 5 and 6 /8 months of  anti-TB treatment at 
an urban out-patient clinic located in Kampala, Uganda.
Methods
Design and setting
This was a cross-sectional study conducted at the Ugan-
da National TB and Leprosy Programme (NTLP) Clinic, 
Mulago National Referral and Teaching Hospital Com-
plex between February and April 2016.
Mulago hospital serves patients from all over Uganda 
and residents of  the surrounding areas in Kampala dis-
trict. The NTLP clinic serves about 60-80 patients per 
month of  whom a quarter are new patients.  The number 
of  patients bacteriologically confirmed each month var-
ies depending on the test used, with about 60-65, 20-28 
and 6-12 patients confirmed using Gene Xpert,sputum 
smear, and solid culture respectively.   The clinic provides 
out-patient and in-patient care to PTB patients of  all cat-
egories including new, relapse, and continuation phase. 
Patients are followed up regularly as per national treat-
ment guidelines that is to say at diagnosis (0), 2, 5, 6, 8 
months after starting treatment and wherever it is neces-
sary. Patient follow-up clinic visits entail drug refills, con-
sultation, and management of  any arising complications 
including adverse effects according to the national TB 
program guidelines13.
Eligibility criteria
We included all adults (≥18 years) with PTB at either: 
diagnosis (0) or at 2, 5, 6 /8 months of  treatment. Myco-
bacterium tuberculosis was bacteriologically confirmed either 
with Gene Xpert, Sputum smear, or culture. For partici-
pants at diagnosis, their current diagnostic result was con-
sidered. Among those at 2 , 5, 6/ 8 months of  treatment, 
their patient charts were retrieved and  initial diagnostic 
result before starting treatment was considered before en-
rollment into the study. All participants provided signed 
informed consent before enrolment into the study. We 
excluded participants taking any lipid-lowering drugs for 
example statins and fibrates, and those who were very ill 
with the kanorffsky score less than 20% at the time of  
enrollment.
Sample size calculation
We estimated a sample size of  427 adults using the Kish 
Leslie formula14, assuming a 50% prevalence rate, 0.05 
precision level, and factoring for 10% non-response.
Sampling procedure
The participants were consecutively enrolled with no 
stratification according to the duration of  treatment.
Data collection 
Study procedures included a complete physical exam-
ination, blood draws for laboratory tests (lipid profile, 
random blood sugar) and administration of  a pre-tested 
structured questionnaire. Information collected on the 
questionnaire included socio-demographic characteris-
tics, nutritional status, co-morbid illnesses, socio-eco-
nomic characteristics, and lifestyle and clinical factors.
We drew 4mls of  venous blood samples from the an-
te-cubital fossa for each participant, 6 hours after the last 
meal to assess the lipid profile and fasting blood sugar. 
The samples for lipid profiles were analyzed using CO-
BAS 6000 (Roche Diagnostics Ltd) at Mulago Hospital 
clinical chemistry laboratory. A Fasting blood sugar was 
measured on-site using a SOFTSTYLE® glucometer in 
accordance with standard operating procedures.  All par-
ticipants included in the study had undergone a test for 
HIV infection following the national  HIV serial testing 
algorithm15.
We also took anthropometric measurements such as 
height and weight. Weight was taken using an adult SECA 
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digital electronic scales to the nearest 100g. Height was 
measured to the nearest cm of  standing height using a 
stadiometer. All anthropometric measurement values 
were means of  duplicates. Body Mass Index (BMI) was 
calculated as weight divided by height in meters squared.
The participants recruited at diagnosis had a posteroan-
terior chest X-ray taken as per national guidelines. For 
patients enrolled at 2, 5, 6 or 8 months of  treatment, their 
initial chest X-rays at diagnosis were retrieved from the 
repository and read.
Data management and analysis plan
Data were double entered into Epidata version 3.1 and 
analyzed using STATA version 12.0 (Stata Corp College 
Station TX, USA). Categorical variables were summarized 
using proportions while means, median and inter-quartile 
range were used to summarize continuous variables. The 
prevalence of  hypocholesterolemia was defined as the 
proportion of  individuals with total serum cholesterol 
levels less than 3.7 mmol/l amongst the total number of  
participants included in the study. A Diagnosis of  dia-
betes mellitus was made if  a participant had a six-hour 
fasting blood sugar ≥126 mg/dl16.
We estimated prevalence ratios in bivariate and multi-
variate analyses using a generalized linear model with a 
log identity and binomial link. Participants with hyper-
cholesterolemia (total serum cholesterol levels more than 
5.7mmol/l), were excluded from further analysis in as-
sessing for factors associated.  Clinical significance and a 
cut-off    P value of  ≤ 0.25  during bivariate analyses were 
used to select variables for multivariate analysis9,17,18.  Two-
way product terms were formed among the variables in 
the model to assess for interaction using the chunk test. 
We also assessed for confounding by checking for a 10% 
change in the effect measure.
Ethical consideration
Ethical approval was obtained from the Makerere Uni-
versity School of  Medicine Research and Ethics Commit-
tee (#REC REF 2016-017). All patients provided written 
informed consent. All study data were kept under lock 
and key to maintain privacy and confidentiality. We also 
referred all participants with hypocholesterolemia to cli-
nicians for nutritional counseling.
Results
Description of  the study population
Of  the 371 participants screened, 323 were included in 
the study (Figure 1). Most of  the participants were male 
(63.2%), and Catholics (35.9%). The median age of  the 
participants was 30 years, Inter Quartile Range (23-39), 
(Table 1). Figure 1: The rofile of TB pati nts enrolled in the study at
Mulago Hospital TB ward, February –April 2016
Total number screened - 371 
Enrolled 335 participants
323 participants were 
included in the analysis 
32 had extra pulmonary TB
2 declined to consent
2 were too ill to complete the 
interview




Figure 1: The profile of  TB patients enrolled in the study at
Mulago Hospital TB ward, February –April 2016
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Table 1. Socio-demographic characteristics of the study participants with PTB at Mulago 
Hospital, Kampala February –April 2016 (N=323) 
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*included those who had no religion, traditionalist 
**includes self -employed, salaried employee and peasant farmers  
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About 64.1 % of  participants had normal BMI (18.5-
24.5), 31.9 % were HIV positive and 27.9 % had cavi-
ties on chest X-ray (Table 2).  About 95.2 % of  the HIV 
positive participants were currently taking anti-retroviral 
drugs.
Table 2. Clinical characteristics of the study participants with bacteriologically confirmed 
TB at diagnosis and during Anti TB treatment at Mulago Hospital Kampala, February –
April 2016. (N=323) 
  Characteristic Frequency Percentage   
  Duration of Anti-TB treatment       
  Diagnosis 89 27.6   
  2 months 93 28.8   
  5 months 82 25.4   
  6/8 months 59 18.2   
  HIV infection status       
  Positive 103 31.9   
  Negative 220 68.1   
  Confirmation of TB disease  
 
  
  Sputum Smear grade  
 
  
  AFB 1+ 58 17.9   
  AFB 2+ 52 16.1   
  AFB 3+ 46 14.2   
  Gene Xpert 157 48.7   
  Sputum culture* 10 3.1   
  Body mass index(BMI)     
  <18.5 82 25.4   
  18.5-24.5 207 64.1   
  >24.5 34 10.5   
  Chest X-ray  
 
  
  Cavities 89 27.9   
  No cavities** 230 72.1   
  Diabetes Mellitus     
  No 283 87.6   
  Yes 40 12.38   
  ART use(n=103)     
  Currently on ARVs 98 95.2   
        Not on ARVs     5 4.8 
  Type of ARVs(n=98)     
  Protease Inhibitors 3 3.0   
  NNRTIs 95 97.0   
  Smoking status     
  ever smoked 54 16.7   
  Never smoked 269 83.3   
  Alcohol intake     
  Currently drink 52 16.1   
  Do not drink 271 83.9   
  Hypertension     
  No 287 88.9   
  Yes 36 11.1   
           * had only culture results at entry into the study 
** Includes infiltrates, hilar lymphadenopathy, pleural effusions, normal findings, and 4 participants had missing chest x-rays. 
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Prevalence of  hypocholesterolemia and associated 
factors.
The prevalence of  hypocholesterolemia among the study 
participants was 43.6 % (95 % CI: 38.3-49.2).  This was 
highest amongst those at diagnosis (57.3 %) and lowest 
(32.2 %) among those at 6/8 months that is to say the end 
of  treatment (Table 3).
Table 3. Proportions of participants with cholesterol abnormalities at diagnosis and during anti- TB treatment  
among PTB adults attending Mulago Hospital, February-April, 2016 
  
Total serum 
cholesterol Diagnosis (n=89) 
2 months 




( <3.7mmol/l), n 51 40 31 19 141 
(proportion,95 
% CI) (57.3, 46.76-67.22) (43.0,33.28-53.32) (37.8, 27.92-48.8) (32.2, 21.46-45.23) (43.65, 38.31-    49.15) 
Normal (3.7-
57mmol/l),n 35 47 48 34 164 
(proportion,95 
% CI) (39.33, 29.67-49.89)  (50.5, 40.40-60.63) (58.5,  47.53-68.75) (57.6,44.64-69.64 (50.8, 45.31-56.22) 
High (>5.7 
mmol/l),n 3 6 3 6 18 
(proportion,95 
% CI) (3.3,1.07-10.03) (6.6, 2.91-1.37) (3.7, 1.17-10.85) (10.2,4.59-21.02) (5.6, 5.53-8.69) 
  
The Bivariate analysis showed that having diabetes mel-
litus was associated with a 44% increased risk of  hypo-
cholesterolemia (PR: 1.44, 95 % CI (1.09, 1.90) compared 
to those without diabetes mellitus. Being greater than 30 
years old increased the risk of  having hypocholesterolemia 
by 9 % (PR: 1.09, 95 % CI (0.86, 1.40) when compared to 
those less than 30 years. The participants who were HIV 
positive were 0.86 times less likely (PR: 0.86, 95 % CI 
(0.65-1.13) to have hypocholesterolemia when compared 
to their HIV sero-negative counterparts (Table 4). HIV 
status, gender, diabetes, duration of  anti-TB treatment 
and the presence of  cavities were considered for a series 
of  multivariate models based on previous studies, clin-
ical significance and P-value less than 0.25. HIV status, 
diabetes, and presence of  cavities were also considered 
for assessment of  interaction and confounding based 
on biologic plausibility and previous studies7,8. None of  
these variables had any significant interaction terms nor 
meaningful confounding effects. The final model had 
two covariates (Table 4). Being male was associated with 
a 52% statistically significant increase in the prevalence 
of  hypocholesterolemia compared to females (PR=1.52 
95% CI: (1.13-2.03), P=0.005). Participants who had had 
5 months of  treatment were 30% less likely to have hypo-
cholesterolemia (PR=0.71 95% CI: (0.51-0.97), P=0.033) 
when compared to those who were at diagnosis (not yet 
started treatment). Similarly, participants who were at 6/8 
months of  treatment were 35% (PR 0.65, 95% CI: (0.44-
0.97), P=0.033) less likely to have hypocholesterolemia 
when compared to those who were at diagnosis.
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Table 4. Regression analysis of factors associated with hypocholesterolemia among adults 
with PTB at Mulago Hospital, February –April 2016. (N=305) 
  
Characteristic Hypoholesterolemia N (%) 
Normal 
levels N (%) 
Unadjusted , 







HIV infection status 
   
  
      Negative 102 (48.3) 109 (51.6) 1   
     Positive 39 (41.5) 55 (58.5) 0.86 (0.65, 1.13)   
 Gender 
   
  
      Female 37 (33.6) 73 (66.4) 1 1 
 




 Diabetes mellitus 
   
  
          No 117 (43.8) 150 (56.2) 1   
 Yes 24 (63.2) 14 (36.8) 1.44  (1.09, 1.90)   
 
Age 
   
  
     <30 66  (44.0) 84 (56.0) 1   
       >=30 75 (48.4) 80 (51.6) 1.09 (0.86, 1.40)   
 Alcohol status 
   
  
 No 119 (46.1) 139 (53.9) 1   
 Yes 22 (46.8) 25 (53.2) 0.98 (0.71, 1.37)   
 Smoking status 
   
  
         No 117 (45.7) 139 (54.3) 1   
 
        Yes 24 (49.0) 25 (51.0) 
        
 0.93 (0.68, 1.28) 
  
 Duration of TB 
treatment 
   
  
      Diagnosis 51 (59.3) 35 (40.7) 1 1 
 













   
  
      No 124 (45.9 146(54.1) 1   
      Yes 17 (48.6) 18(51.4) 1.05 (0.73,1.52)   
 Chest X-ray 
   
  
    No cavities 102 (46.6) 117 (53.4) 1   
      Cavities 36 (43.9 46 (56.1) 0.94 (0.71,1.25)   
 *PR: Prevalence Ratio 
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Discussion
Nearly half  of  the participants in the study population 
had hypocholesterolemia. This is among the first studies 
to document the prevalence of  hypocholesterolemia in 
TB patients in Uganda.
We found a high prevalence of  hypocholesterolemia 
among the study participants with the highest propor-
tion being detected among those at diagnosis and lowest 
among those who had received 6/8 months of  treatment. 
The high proportions of  hypocholesterolemia at diagno-
sis may be due to inflammation caused by PTB which 
may worsen as the duration of  symptoms and severity 
of  the disease increases19,20. Also, at diagnosis, hypocho-
lesterolemia proportions may be a consequence of  the 
TB disease although it cannot be elucidated whether it 
is a factor contributing to the development of  the active 
disease4. In our study, participants who were at 5 months 
of  anti-TB treatment had slightly higher proportions 
of  hypocholesterolemia when compared to those who 
were at 6/8 months of  treatment (37.8 % versus 32.2 
%) respectively. This is contrary to the expected close 
proportions of  hypocholesterolemia in the two groups. 
This may be due to the fact that those who were at 6/ 
8 months of  treatment received the anti-TB drugs for 
a longer duration and may have received different types 
of  drug regimens. The lowered hypocholesterolemia pro-
portions among participants at 6/8 months (end of  TB 
treatment) may possibly be explained by better response 
to treatment with improved appetite and increased nutri-
ent intake especially of  cholesterol-rich foods like eggs 
and fish.
The study results demonstrated that duration of  anti TB 
treatment was associated with hypocholesterolemia. This 
may be due to the fact that the longer an individual is 
adherent to TB medications, the more their immunity is 
improved leading to reduced metabolic disturbances and 
improved appetite21. This improvement leads to nutri-
tional recovery during the course of  anti-TB treatment.
Males were 52% more likely to develop hypocholesterol-
emia as compared to females. This finding may possibly 
be attributed to the hormonal differences, reduced im-
munity and reduced nutrient intake especially fats which 
may occur differentially among men and women with 
PTB21. The varying poor nutrient uptake in male PTB pa-
tients may probably be mediated by inflammatory mark-
ers released during TB disease (especially tumor necro-
sis factor-alpha) which interacts with human metabolic 
pathways that lead to anorexia22. Furthermore, males in 
our study presented with more severe disease (cavities on 
chest X-ray) possibly leading to a higher predisposition to 
hypocholesterolemia23.
The strength of  this study hinges on the fact that we con-
sidered participants at different time points of  treatment 
which gives a broad spectrum of  dyslipidemias among 
TB patients although a cohort study with larger sample 
size and a homogenous group of  study participants fol-
lowed through time would be the ideal.
The interpretation of  findings from this study should be 
made with caution as it had some limitations. First, we 
studied different sub-populations at varying time points 
of  TB treatment. There could be underlying low levels of  
total serum cholesterol and thus the observed increase in 
mean total serum cholesterol concentrations as the du-
ration of  anti TB treatment may differ if  the same indi-
viduals are followed up over time during care. Further 
misclassification bias was minimized by training of  the 
research assistants, pre-testing the questionnaire before 
data collection, calibration of  the weighing scale and sta-
diometer daily.
It is also important to note that this being a cross-sec-
tional study, causality could not be assessed. However, we 
recruited participants that had taken treatment at vary-
ing time points to mimic a cohort study in temporality. 
Selection bias which may have arisen from referral bias 
since Mulago hospital is a tertiary referral center was min-
imized by recruiting participants from the catchment area 
of  the population. The findings from this study are gen-
eralizable to adults with PTB in African settings seeking 
care at tertiary level health centers.
Conclusion
The overall prevalence of  hypocholesterolemia among 
adult PTB patients presenting at Mulago NTLP clinic in 
Kampala was high. Being male and duration of  anti–Tu-
berculosis treatment were significantly associated with 
hypocholesterolemia. The findings from our study may 
need further evaluation in longitudinal studies employing 
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larger sample sizes to determine the effect of  low total 
serum cholesterol levels on the parameters used to assess 
response to anti-TB treatment like sputum conversion, 
cure, and mortality.
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